共 50 条
- [1] Effect of a monotherapy mit Rimonabant on metabolism position in type-2-diabetes: the SERENADE-studyDIABETOLOGE, 2008, 4 (08): : 652 - 653Rose, B.
- [3] SERENADE: rimonabant monotherapy for treatment of multiple cardiometabolic risk factors in treatment-naive patients with Type 2 diabetesDIABETIC MEDICINE, 2007, 24 : 4 - 4Rosenstock, J.Iranmanesh, A.Hollander, P.
- [4] Rimonabant zur Behandlung des Diabetes mellitus Typ 2SERENADE-StudieRimonabant for the treatment of type 2 diabetes mellitusThe SERENADE studyDer Diabetologe, 2007, 3 (4): : 270 - 277A.F.H. PfeifferP. Bramlage
- [5] Place of Rimonabant in Type 2 diabetesANNALES D ENDOCRINOLOGIE, 2005, 66 (04) : 376 - 376Girault, V
- [6] SERENADE: The Study Evaluating Rimonabant Efficacy in Drug-Naive Diabetic Patients Effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetesDIABETES CARE, 2008, 31 (11) : 2169 - 2176Rosenstock, JulioHollander, PriscillaChevalier, SoazigIranmanesh, Ali
- [7] Effects of monotherapy with Rimonabant on metabolism in type 2 diabetics: The SERENADE study [Effekt einer Monotherapie mit Rimonabant auf die Stoffwechsellage bei Typ-2-Diabetes: die SERENADE-Studie]Der Diabetologe, 2008, 4 (8): : 652 - 653Rose B.
- [8] Rimonabant in obese patients with type 2 diabetesLANCET, 2007, 369 (9561): : 553 - 553Lambert, Marie-LaurenceRoberfroid, DominiqueVlayen, Joan
- [9] Repaglinide as monotherapy in Type 2 diabetesEXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 1999, 107 : S133 - S135Gomis, R